Business Wire

GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficacy results from the pivotal Phase III clinical trial ...
Business Insider

GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

YONGIN, South Korea, Feb. 13, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, ...
Pharmabiz

Mirum Pharma inks pact with GC Pharma to develop and commercialize maralixibat to treat rare liver diseases in South Korea

Mirum Pharmaceuticals and GC Pharma announced that they have entered into an exclusive licensing agreement, pursuant to which GC Pharma has agreed to develop and commercialize maralixibat in South ...